Study summary

The primary purpose of this study is to assess the renal protective effect of ipragliflozin in combination with metformin on the percent change of UACR from baseline to 24 weeks against glimepiride in combination with metformin in type 2 diabetes mellitus patients with albuminuria. The secondary purpose of this study is to assess the efficacy, safety and impact on quality of life (QoL) of ipragliflozin in combination with metformin against glimepiride in combination with metformin in type 2 diabetes mellitus patients with albuminuria.

Additional Study Details

Phase
4
Product
  • metformin
  • ipragliflozin
  • glimepiride
  • Type
    Interventional
    Masking
    None (Open Label)
    Enrollment number
    33
    Show Additional Study Details

    Study documents

    Scientific Results Summary
    Available Language(s): Korean
    Scientific Results Summary 2
    Available Language(s): Korean
    Plain Language Summary
    Available Language(s): Korean

    Get more information

    Would you like more information about clinical trial sites that are recruiting participants for A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus patients with Albuminuria? Contact us by filling out your information to the right and we’ll respond to you.

    • A patient
    • A caregiver
    • A parent
    • A healthcare provider
    • A patient advocate
    • Algeria
    • Argentina
    • Armenia
    • Australia
    • Austria
    • Belarus
    • Belgium
    • Bosnia And Herzegovina
    • Brazil
    • Bulgaria
    • Canada
    • Chile
    • China
    • Colombia
    • Croatia
    • Czech Republic
    • Denmark
    • Dominican Republic
    • Egypt
    • Estonia
    • Finland
    • Former Serbia and Montenegro
    • France
    • Georgia
    • Germany
    • Greece
    • Guatemala
    • Hong Kong
    • Hungary
    • Iceland
    • India
    • Indonesia
    • Ireland
    • Israel
    • Italy
    • Japan
    • Jordan
    • Kazakhstan
    • Latvia
    • Lebanon
    • Lithuania
    • Macedonia
    • Malaysia
    • Mexico
    • Montenegro
    • Morocco
    • Netherlands
    • New Zealand
    • Norway
    • Panama
    • Peru
    • Philippines
    • Poland
    • Portugal
    • Puerto Rico
    • Republic of Korea
    • Republic of Moldova
    • Romania
    • Russian Federation
    • Saudi Arabia
    • Serbia
    • Singapore
    • Slovakia
    • Slovenia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Taiwan, Province of China
    • Thailand
    • Turkey
    • Ukraine
    • United Kingdom
    • United States
    • Vietnam

    By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

      Locations

      Contact Us
      Contact Us
      Completed
      Site 02
      Deagu, Republic of Korea
      Completed
      Site 07
      Seoul, Republic of Korea
      Withdrawn
      Site 10
      Seoul, Republic of Korea
      Withdrawn
      Site 06
      Daejeon, Republic of Korea
      Withdrawn
      Site 15
      Bucheon-si, Republic of Korea
      Completed
      Site 12
      Suwon-si, Republic of Korea
      Withdrawn
      Site 17
      Seoul, Republic of Korea
      Withdrawn
      Site 04
      Bucheon-si, Gyueonggi-do, Republic of Korea
      Completed
      Site 11
      Guri-si, Republic of Korea
      Completed
      Site 05
      Seoul, Republic of Korea
      Withdrawn
      Site 03
      Goyang-si, Gyueonggi-do, Republic of Korea
      Completed
      Site 09
      Seoul, Republic of Korea
      Withdrawn
      Site 18
      Seoul, Republic of Korea
      Completed
      Site 13
      Busan, Republic of Korea
      Withdrawn
      Site 08
      Gwangju, Republic of Korea
      Withdrawn
      Site 14
      Seoul, Republic of Korea
      Completed
      Site 01
      Seoul, Republic of Korea

      Frequently Asked Questions

      Are clinical trials only for people with advanced cancer?

      While some clinical trials may focus on more advanced cancers, many trials are open to patients at various stages of their cancer. Each study has rules about who can take part. For example, only patients in a certain age group or those who have a certain type of tumor may be able to join.

      Will I have to stop my current treatment to participate in a clinical trial?

      Sometimes researchers want participants to keep taking their current treatments during a clinical trial. Other times, you may need to stop your current treatments for a while. If the investigational treatment doesn't work, you can usually go back to your original treatment plan.

      Should I be worried about getting a placebo?

      In cancer clinical trials, a placebo is only used if there is no other treatment for that type of cancer. This helps compare an investigational treatment to the placebo. Placebos are rarely used in cancer trials because the best available treatment, called the “standard of care”, is usually given instead.

      Do I need a referral from my doctor to take part in a study?

      Your doctor may not know about all the opportunities for clinical trials that are available to you. Talk to your doctor or other medical provider about clinical trial information that you find. They can help you decide if a clinical trial is right for you. If you do not find any options on this website, we recommend you visit an online public registry website like clinicaltrials.gov to see a wide variety of available clinical trials.

      Explore More

      1

      What are clinical trials?

      2

      Why are Clinical Trials Important?

      3

      Why Participate in a Clinical Trial?